Global Sarcopenia Market 2018: What is the Current Trend and size of the Market? || forecast to 2027

The Latest Pharmaceuticals Report Sarcopenia Market dealing with all information of the therapeutics under development, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report conjointly covers the descriptive pharmacological action of the therapeutics, its complete analysis and development history and latest news and press releases. in addition, the report provides an outline of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.

Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength and function. Sarcopenia is a component of the frailty syndrome. It is often a component of cachexia. It can also exist independently of cachexia; whereas cachexia includes malaise and is secondary to an underlying pathosis (such as cancer), sarcopenia may occur in healthy people and does not necessarily include malaise.

Signs and Symptoms include weakness, loss of endurance and poor balance. Causes of sarcopenia include a reduction in the nerve cells, low hormone levels and decline in body’s ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise and dietary supplements.

Simple circumference measurement does not provide enough data to determine whether or not an individual is suffering from severe sarcopenia. Sarcopenia is also marked by a decrease in the circumference of distinct types of muscle fibers. Skeletal muscle has different fiber-types, which are characterized by expression of distinct myosin variants. During sarcopenia, there is a decrease in "type 2" fiber circumference (Type II), with little to no decrease in "type I" fiber circumference (Type I), and deinervated type 2 fibers are often converted to type 1 fibers by reinnervation by slow type 1 fiber motor nerves.

For more detailed Information Visit at: https://www.marketreportsworld.com/10918373

Sarcopenia diseases Causes: Satellite cells are small mononuclear cells that abut the muscle fiber. Satellite cells are normally activated upon injury or exercise. These cells then differentiate and fuse into the muscle fiber, helping to maintain its function. One theory is that sarcopenia is in part caused by a failure in satellite cell activation. Extreme muscle loss is often a result of both diminishing anabolic signals, such as growth hormone and testosterone, and promotion of catabolic signals, such as pro-inflammatory cytokines. Oxidized proteins increase in skeletal muscle with age and leads to a buildup of lipofuscin and cross-linked proteins that are normally removed via the proteolysis system. These proteins compile in the skeletal muscle tissue, but are dysfunctional. This leads to an accumulation of non-contractile material in the skeletal muscle. This helps explain why muscle strength decreases severely, as well as muscle mass, in sarcopenia. One group has suggested that the evolutionary basis for the failure of the body to maintain muscle mass and function with age is that the genes governing these traits were selected in a Late Paleolithic environment in which there was a very high level of obligatory muscular effort, and that these genetic parameters are therefore ill-matched to a modern lifestyle characterized by high levels of lifelong sedentary behavior.Epidemiological research into the developmental origins of health and disease has shown that early environmental influences on growth and development may have long-term consequences for human health. Low birth weight, a marker of a poor early environment, is associated with reduced muscle mass and strength in adult life. One study has shown that lower birth weight is associated with a significant decrease in muscle fibre score, suggesting that developmental influences on muscle morphology may explain the widely reported associations between lower birth weight and sarcopenia.

Classification: The ICD-10 Clinical Modification (ICD-10-CM), which is the United States' national adaptation of ICD-10, classifies sarcopenia to code M62.84. (This is an enhancement over the base ICD-10 classification, which only uses the 5th character position within Chapter XVII to identify the anatomical site of occurrence. The European Working Group on Sarcopenia in Older People (EWGSOP) developed a clinical definition and consensus diagnostic criteria for age-related sarcopenia, using the presence of low muscle mass and either low muscular strength or low physical performance. Severe sarcopenia requires the presence of all three conditions.

Epidemiology:

A study, in community dwelling older adults with an average age of 67 years, found the UK prevalence of sarcopenia to be 4.6% in men and 7.9% in women using the EWGSOP approach. Another study, conducted in the United States among older adults with an average age of 70.1 years, found the prevalence of sarcopenia to be 36.5%. Sarcopenia affects about half of people over 80 in New Mexico.

Sarcopenia Market Insights, Epidemiology and Market Forecast studies the present scenario of market (with the base year being 2018), Key Cross Competition, and the growth prospects of global Sarcopenia market for 2018-2027.

Pipeline Products covered across the following Developmental Stages:

Clinical
Non-clinical
Inactive: Discontinued and/or Dormant
Key points Covered in this Report:

Sarcopenia Market (7MM) and forecasting
Sarcopenia Sales forecasting
Sarcopenia Market segments
Sarcopenia Epidemiology
Pipeline products and technologies
Sarcopenia Competitive landscape, SWOT analysis
Sarcopenia Market Driver’s and barriers
Sarcopenia Key Companies and Funding
Markets Covered:

United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Request a Sample of Sarcopenia Market research report from:

https://www.marketreportsworld.com/enquiry/request-sample/10918373

Additionally, the Report highlights the frontrunners, the drivers and barriers for the Sarcopenia market, as well as treatment algorithm, current treatments & advancements are included.

Points covered in the Sarcopenia Market research reports:

Chapter 1: This chapter contents Sarcopenia Market Report Introduction

Chapter 2: Sarcopenia Market Overview at a Glance with Total Market Share Distribution of Sarcopenia for 7 MM in 2016 and Total Market Share Distribution of Sarcopenia for 7 MM in 2027

Have a Query, Ask our expert:

https://www.marketreportsworld.com/enquiry/pre-order-enquiry/10918373

Chapter 3: Sarcopenia Overview, Symptoms, Pathophysiology, Staging, Diagnosis and Treatment

Chapter 4: Epidemiology and Patient Population in US, Diagnosed Cases of Sarcopenia in US, Germany, France, Italy, Spain, United Kingdom are described.

Chapter 5: this section studies Treatment Algorithm along with Treatment Guidelines/Practices

Chapter 6: Marketed Drugs for Sarcopenia with Drug Description, MOA Regulatory Milestones, Advantages & Disadvantages, Safety and Efficacy, Product Profile, Patent Status of different company are studied.

Chapter 7-10. Emerging Therapies, Overview of Total Sarcopenia Market (2018 & 2027), Sarcopenia: Country-Wise Market Analysis, Market Drivers, Market Restraints is explained in this section.

Price of Report: $6250(Single User Licence)

Purchase the Sarcopenia Market Report at:

https://www.marketreportsworld.com/purchase/10918373

The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Sarcopenia in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Detailed TOC of Sarcopenia- Market Insight, Epidemiology and Market Forecast - 2027

Report Introduction
Sarcopenia Market Overview at a Glance
2.1. Market Share Distribution of Sarcopenia in 2017

2.2. Market Share Distribution of Sarcopenia in 2027

Disease Background and Overview: Sarcopenia
Epidemiology and Patient Population
4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Sarcopenia in 7MM

4.3. Total Prevalent Patient Population of Sarcopenia in 7MM – By Countries

Epidemiology of Sarcopenia by Countries
5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Sarcopenia

5.1.3. Sub-Type Specific cases of the Sarcopenia *

5.1.4. Sex- Specific Cases of the Sarcopenia*

5.1.5. Diagnosed Cases of the Sarcopenia

5.1.6. Treatable Cases of the Sarcopenia

5.2. EU5

5.3. Assumptions and Rationale

5.4. Germany

5.4.1. Assumptions and Rationale

5.4.2. Prevalent/Incident Cases of the Sarcopenia

5.4.3. Sub-Type Specific cases of the Sarcopenia*

5.4.4. Sex- Specific Cases of the Sarcopenia*

5.4.5. Diagnosed Cases of the Sarcopenia

5.4.6. Treatable Cases of the Sarcopenia

5.5. France

5.5.1. Assumptions and Rationale

5.5.2. Prevalent/Incident Cases of the Sarcopenia

5.5.3. Sub-Type Specific cases of the Sarcopenia*

5.5.4. Sex- Specific Cases of the Sarcopenia*

5.5.5. Diagnosed Cases of the Sarcopenia

5.5.6. Treatable Cases of the Sarcopenia

5.6. Italy

5.6.1. Assumptions and Rationale

5.6.2. Prevalent/Incident Cases of the Sarcopenia

5.6.3. Sub-Type Specific cases of the Sarcopenia*

5.6.4. Sex- Specific Cases of the Sarcopenia*

5.6.5. Diagnosed Cases of the Sarcopenia

5.6.6. Treatable Cases of the Sarcopenia

5.7. Spain

5.7.1. Assumptions and Rationale

5.7.2. Prevalent/Incident Cases of the Sarcopenia

5.7.3. Sub-Type Specific cases of the Sarcopenia*

5.7.4. Sex- Specific Cases of the Sarcopenia*

5.7.5. Diagnosed Cases of the Sarcopenia

5.7.6. Treatable Cases of the Sarcopenia

5.8. United Kingdom

5.8.1. Assumptions and Rationale

5.8.2. Prevalent/Incident Cases of the Sarcopenia

5.8.3. Sub-Type Specific cases of the Sarcopenia*

5.8.4. Sex- Specific Cases of the Sarcopenia*

5.8.5. Diagnosed Cases of the Sarcopenia

5.8.6. Treatable Cases of the Sarcopenia

5.9. Japan

5.9.1. Assumptions and Rationale

5.9.2. Prevalent/Incident Cases of the Sarcopenia

5.9.3. Sub-Type Specific cases of the Sarcopenia*

5.9.4. Sex- Specific Cases of the Sarcopenia*

5.9.5. Diagnosed Cases of the Sarcopenia

5.9.6. Treatable Cases of the Sarcopenia

Current Treatment & Medical practices
6.1. Treatment Algorithm

6.2. Treatment Guidelines

Unmet Needs of the Sarcopenia
Marketed Therapies
8.1. Drug A: Company 1

8.1.1. Drug Description

8.1.2. Mechanism of Action

8.1.3. Regulatory Milestones

8.1.4. Advantages & Disadvantages

8.1.5. Product Profile

8.2. Drug B: Company 2

8.2.1. Drug Description

8.2.2. Mechanism of Action

8.2.3. Regulatory Milestones

8.2.4. Advantages & Disadvantages

8.2.5. Product Profile

Pipeline Therapies – At a glance
Key Cross Competition
Emerging Therapies for Sarcopenia
11.1. Drug C: Company 3

11.1.1. Drug Description

11.1.2. Clinical Trials Details

11.1.3. Safety and Efficacy Profile

11.1.4. Advantages & Disadvantages

11.1.5. Pipeline Development Activities

11.1.6. Product Profile

11.2. Drug D: Company 4

11.2.1. Drug Description

11.2.2. Clinical Trials Details

11.2.3. Safety and Efficacy Profile

11.2.4. Advantages & Disadvantages

11.2.5. Pipeline Development Activities

11.2.6. Product Profile

Sarcopenia: 7MM Market Analysis
12.1. 7MM Market Size of Sarcopenia

12.2. 7MM Percentage Share of drugs marketed for Sarcopenia

12.3. 7MM Market Sales of Sarcopenia by Products

Sarcopenia: Country-Wise Market Analysis
13.1. United States

13.1.1. Market Size of Sarcopenia in United States

13.1.2. Percentage Share of drugs marketed for Sarcopenia in United States

13.1.3. Market Sales of Sarcopenia by Products in United States

13.1.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2. EU-5

13.2.1. Germany

13.2.1.1. Market Size of Sarcopenia in Germany

13.2.1.2. Percentage Share of drugs marketed for Sarcopenia in Germany

13.2.1.3. Market Sales of Sarcopenia by Products in Germany

13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.2. France

13.2.2.1. Market Size of Sarcopenia in France

13.2.2.2. Percentage Share of drugs marketed for Sarcopenia in France

13.2.2.3. Market Sales of Sarcopenia by Products in France

13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.3. Italy

13.2.3.1. Market Size of Sarcopenia in Italy

13.2.3.2. Percentage Share of drugs marketed for Sarcopenia in Italy

13.2.3.3. Market Sales of Sarcopenia by Products in Italy

13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.4. Spain

13.2.4.1. Market Size of Sarcopenia in Spain

13.2.4.2. Percentage Share of drugs marketed for Sarcopenia in Spain

13.2.4.3. Market Sales of Sarcopenia by Products in Spain

13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.5. United Kingdom

13.2.5.1. Market Size of Sarcopenia in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Sarcopenia in United Kingdom

13.2.5.3. Market Sales of Sarcopenia by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

13.3. Japan

13.3.1. Market Size of Sarcopenia in Japan

13.3.2. Percentage Share of drugs marketed for Sarcopenia in Japan

13.3.3. Market Sales of Sarcopenia by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

Market Drivers
Market Barriers
Appendix
Report Methodology
List of Tables and Charts Available in Sarcopenia- Market Insight, Epidemiology and Market Forecast – 2027:

Table 1: Total Prevalent/Incident Cases of the Sarcopenia in 7MM

Table 2: Total Prevalent/Incident Cases of the Sarcopenia in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Sarcopenia in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Sarcopenia in United States (2016-2027)

Table 5: Sex- Specific Cases of the Sarcopenia in United States (2016-2027)

Table 6: Diagnosed Cases of the Sarcopenia in United States (2016-2027)

Table 7: Treatable Cases of the Sarcopenia in United States (2016-2027)

Table 8: Prevalent/Incident Cases of the Sarcopenia in Germany (2016-2027)

Table 9: Sub-Type Specific cases of the Sarcopenia in Germany (2016-2027)

Table 10: Sex- Specific Cases of the Sarcopenia in Germany (2016-2027)

Table 11: Diagnosed Cases of the Sarcopenia in Germany (2016-2027)

Table 12: Treatable Cases of the Sarcopenia in Germany (2016-2027)

Table 13: Prevalent/Incident Cases of the Sarcopenia in France (2016-2027)

Table 14: Sub-Type Specific cases of the Sarcopenia in France (2016-2027)

Table 15: Sex- Specific Cases of the Sarcopenia in France (2016-2027)

Table 16: Diagnosed Cases of the Sarcopenia in France (2016-2027)

Table 17: Treatable Cases of the Sarcopenia in France (2016-2027)

Table 18: Prevalent/Incident Cases of the Sarcopenia in Italy (2016-2027)

Table 19: Sub-Type Specific cases of the Sarcopenia in Italy (2016-2027)

Table 20: Sex- Specific Cases of the Sarcopenia in Italy (2016-2027)

Table 21: Diagnosed Cases of the Sarcopenia in Italy (2016-2027)

Table 22: Treatable Cases of the Sarcopenia in Italy (2016-2027)

Table 23: Prevalent/Incident Cases of the Sarcopenia in Spain (2016-2027)

Table 24: Sub-Type Specific cases of the Sarcopenia in Spain (2016-2027)

Table 25: Sex- Specific Cases of the Sarcopenia in Spain (2016-2027)

Table 26: Diagnosed Cases of the Sarcopenia in Spain (2016-2027)

Table 27: Treatable Cases of the Sarcopenia in Spain (2016-2027)

Table 28: Prevalent/Incident Cases of the Sarcopenia in UK (2016-2027)

Table 29: Sub-Type Specific cases of the Sarcopenia in UK (2016-2027)

Table 30: Sex- Specific Cases of the Sarcopenia in UK (2016-2027)

Table 31: Diagnosed Cases of the Sarcopenia in UK (2016-2027)

Table 32: Treatable Cases of the Sarcopenia in UK (2016-2027)

Table 33: Prevalent/Incident Cases of the Sarcopenia in Japan (2016-2027)

Table 34: Sub-Type Specific cases of the Sarcopenia in Japan (2016-2027)

Table 35: Sex- Specific Cases of the Sarcopenia in Japan (2016-2027)

Table 36: Diagnosed Cases of the Sarcopenia in Japan (2016-2027)

Table 37: Treatable Cases of the Sarcopenia in Japan (2016-2027)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Sarcopenia in USD MM (2016-2027)

Table 42:7MM- Market Share Sarcopenia by Therapies in USD MM (2016-2027)

Table 43:7MM- Market Sales of Sarcopenia by Therapies in USD MM (2016-2027)

Table 44: United States-Market Size of Sarcopenia in USD MM (2016-2027)

Table 45: United States-Market Share Sarcopenia by Therapies in USD MM (2016-2027)

Table 46: United States-Market Sales of Sarcopenia by Therapies in USD MM (2016-2027)

Table 47: Germany-Market Size of Sarcopenia in USD MM (2016-2027)

Table 48: Germany-Market Share Sarcopenia by Therapies in USD MM (2016-2027)

Table 49: Germany-Market Sales of Sarcopenia by Therapies in USD MM (2016-2027)

Table 50: France-Market Size of Sarcopenia in USD MM (2016-2027)

Table 51: France-Market Share Sarcopenia by Therapies in USD MM (2016-2027)

Table 52: France-Market Sales of Sarcopenia by Therapies in USD MM (2016-2027)

Table 53: Italy-Market Size of Sarcopenia in USD MM (2016-2027)

Table 54: Italy-Market Share Sarcopenia by Therapies in USD MM (2016-2027)

Table 55: Italy-Market Sales of Sarcopenia by Therapies in USD MM (2016-2027)

Table 56: Spain-Market Size of Sarcopenia in USD MM (2016-2027)

Table 57: Spain-Market Share Sarcopenia by Therapies in USD MM (2016-2027)

Table 58: Spain-Market Sales of Sarcopenia by Therapies in USD MM (2016-2027)

Table 59:UK-Market Size of Sarcopenia in USD MM (2016-2027)

Table 60:UK-Market Share Sarcopenia by Therapies in USD MM (2016-2027)

Table 61:UK-Market Sales of Sarcopenia by Therapies in USD MM (2016-2027)

Table 62: Japan-Market Size of Sarcopenia in USD MM (2016-2027)

Table 63: Japan-Market Share Sarcopenia by Therapies in USD MM (2016-2027)

Table 64: Japan-Market Sales of Sarcopenia by Therapies in USD MM (2016-2027)

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided today's businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. Market Reports World is the credible source for gaining the market reports that will provide you with the lead your business needs.

3rd Floor, Silver Spring, Sahyadri farms,
Opp Prabhavee Tech Park,
Baner - Mhalunge Road, Baner, Pune 411045

This release was published on openPR.